Launch of the long-term management plan “Atelier2050” and the medium-term management plan “Vista2027”
First written in FY2022. 6 of 7 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Under the first strategy, "Expanding profits from existing businesses," we will concentrate management resources, including through M&A, on the Functional Materials and Agricultural Chemicals segments, where growth is expected, promote sales and development of existing and new products, and seek to maximize profits.」
For Vista2027 Stage II, the company specified the execution of its 3 basic strategies, including concentrated investment in functional materials and agricultural chemicals, expanded semiconductor supply capacity, overseas expansion of agrochemicals, and reductions in chemical product costs. - FY2025AdvancedAnnual report
「In April 2025, our group launched Stage II, covering the latter 3 years (fiscal 2025 to fiscal 2027). We set targets for the final year, fiscal 2027, of ¥293.0 billion in revenue and ¥65.0 billion in operating profit, identified the creation of new products as our highest-priority issue, and established the following 3 basic strategies.」
Vista2027 Stage II was launched, with targets for fiscal 2027 revenue and operating profit and 3 strategies centered on creating new products as the highest-priority issue: "Expanding profits from existing businesses," "Developing new products with 2030 in sight," and "Strengthening the business platform." - FY2024AdvancedAnnual report
「Fiscal 2024 will be the year in which we review the Stage II plan, covering the latter 3 years of Vista2027. ... We will thoroughly analyze the causes of variances from Stage I and identify the issues, carefully review our strategies, measures and action plans, and formulate a plan for sustainable growth.」
Based on progress under Vista2027 Stage I, fiscal 2024 was positioned as the year to review the Stage II plan, leading to analysis of the causes of variances, identification of issues, and a review of strategies and action plans. - FY2023AdvancedAnnual report
「Under the first strategy, "Deepening business domains and strengthening marketing capabilities," the company established a Biologicals Group at its Biological Science Research Institute in April 2022. Under the fourth strategy, "Expanding the share and profitability of existing businesses," the company is promoting the global expansion of the insecticide Gracia in Asian countries including Japan, South Korea and India, as well as in the Middle East and Africa.」
For the four Vista2027 strategies, the company presented measures already in the execution phase, including establishing the Biologicals Group, expanding Gracia globally, starting sales and production operations in India, and establishing a new manufacturing site in South Korea. - FY2022First statedAnnual report
「In response to major changes in the business environment, the Company returned to its corporate philosophy and launched the long-term management plan "Atelier2050," with a longer-term perspective extending to 2050, together with the medium-term management plan "Vista2027," which sets out the Company's position in 2027 as a milestone, starting in April of this year.」
As new long-term and medium-term management plans following Progress2030 and Vista2021, the company established its vision for 2050 and an interim milestone for 2027.